New cholesterol drug RN5681 enters first human tests

NCT ID NCT07347678

Recruiting now Disease control Sponsor: Ikaria Bioscience Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called RN5681 in 60 healthy adults to see if it is safe and how the body handles it. Participants receive either a single injection of RN5681 or a placebo. The study also looks at how the drug affects cholesterol levels, but the main focus is safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RN5681 (an investigational drug given as an injection under the skin)
What this could lead to: If successful, this could lead to a new treatment option for lowering high cholesterol, potentially reducing heart disease risk.
What could go wrong: This is an early Phase 1 trial with only 60 healthy volunteers, so it's too soon to know if the drug works or is safe for patients. The main goal is safety, not effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH CHOLESTEROL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH CHOLESTEROL

Contacts and locations

Locations

Nucleus Network Pty Ltd.
RECRUITING

Melbourne, Victoria, 3004, Australia
Q-Pharm Pty Ltd.
RECRUITING

Brisbane, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.